DexCom Inc at JPMorgan Healthcare Conference Transcript
Good morning, everyone. Welcome to the JPMorgan Healthcare Conference. I'm Robbie Marcus, the med tech analyst.
I'm very happy to have DexCom here to kick off the medical device track here at the conference. Proud to introduce Kevin Sayer, President, Chairman and CEO of DexCom.
Thank you very much, Robbie. It's a pleasure to be here today. Actually, I think this is the fifth time I've been here as the CEO of DexCom to make this presentation. I'm pretty excited to start the presentation off the same way I've started the other 5. 2019 was a record year for DexCom. As CGM continues to drive therapy and the momentum grows, our business continues to perform beyond our expectations.
Let's talk a bit about the 2019 numbers. Revenue for 2019, for instance, can be approximately $1.47 billion. That's 42% over our 2018 numbers. In the fourth quarter, our estimated revenues were approximately $457 million,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |